No menu items!

Glaxo asks Brazil’s health regulator for emergency use of Sotrovimab Covid-19 drug

RIO DE JANEIRO, BRAZIL - The National Health Regulatory Agency (Anvisa) received, on Monday (19), a request for emergency use of the drug Sotrovimab, a monoclonal antibody developed for the treatment of Covid-19. The request was submitted by the laboratory Glaxo Smith Kline.

https://www.youtube.com/watch?v=Xz8VgVlkZQs&ab_channel=KhaleejTimes

The deadline for analyzing the request is 30 days, counting from the confirmation that all the necessary documents have been delivered. According to Anvisa, the drug has not had clinical studies conducted in Brazil so far.

UAE FINDS DRUG IS 100% SUCCESSFUL AT PREVENTING DEATHS

Between 30 . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?

Check out our other content